Results 261 to 270 of about 2,292,114 (394)

Volumetric mass transfer and dilution rate as key parameters for sustainable industrial syngas fermentation to isopropyl alcohol: modeling and parametric assessment

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Synthesis gas fermentation is a promising route for the valorization of steel mill off‐gas and for replacing conventional fossil‐based isopropyl alcohol (IPA) production. A recent 120 L pilot‐scale study reported 85% gas conversion at 90% product selectivity and claimed a negative global warming potential (GWP) without detailed process design.
Gijs J. A. Brouwer   +3 more
wiley   +1 more source

Sustainable and cost‐effective process design for energy‐self‐sufficient ethyl lactate production from sugar mill feedstocks: a techno‐economic approach

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Bio‐based ethyl lactate (EL) can replace several fossil‐derived products owing to its low toxicity, high solvent functionality, and environmental advantages. This study assesses the techno‐economic viability and greenhouse gas (GHG) reduction potential of producing EL from sugarcane A‐molasses and lignocelluloses in an energy self‐sufficient ...
Motshamonyane J. Phasha   +2 more
wiley   +1 more source

Process development priorities for scaling up direct microbial conversion of sugars into value‐added biochemicals

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The study identified process development priorities toward the feasible production of five value‐added biochemicals in a sugarcane biorefinery based on achievable bioconversion performances. Multiple process scenarios using A‐molasses as feedstock were simulated in Aspen Plus® via direct microbial conversions.
Manasseh K. Sikazwe   +2 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy